|
Barriers to the dissemination and implementation of the results of the Magpie Trial results by country group* |
||||
| Barrier |
Number of countries from which at least one representative gave a response |
|||
|
|
||||
| Low and lower-middle income countries (n = 13#) |
Upper-middle income countries (n = 3#) |
High-income countries (n = 8#) |
Total |
|
|
|
||||
| Political barriers |
8 |
2 |
2 |
12 |
| Lack of information or awareness regarding magnesium sulphate |
6 |
2 |
1 |
9 |
| Costs of treatment |
5 |
2 |
1 |
8 |
| Lack of availability of personnel and hospitals |
5 |
1 |
1 |
7 |
| Lack of support from public authorities |
4 |
1 |
2 |
7 |
| Lack of availability of magnesium sulphate |
5 |
0 |
1 |
6 |
| Lack of clinical practice guidelines |
1 |
1 |
3 |
5 |
| Magnesium sulphate not registered for treatment of eclampsia/pre-eclampsia |
1 |
1 |
0 |
2 |
|
* 17 respondents either did not reply or had illegible responses to this question. # Total number of countries in this group. | ||||
Aaserud et al. BMC Health Services Research 2005 5:68 doi:10.1186/1472-6963-5-68 |
||||